<DOC>
	<DOCNO>NCT03051932</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled trial . A total 100 patient , 50 per treatment arm , undergo minimally invasive thoracic surgery randomize 1:1 across 2 treatment arm : Ofiramev® ( acetaminophen ) injection 1,000 mg ( 100 mL ) plus patient-controlled analgesia ( PCA ) 100 mL placebo plus PCA .</brief_summary>
	<brief_title>Effects Intravenous Acetaminophen Patients Undergoing Thoracoscopic Surgery</brief_title>
	<detailed_description>This single-center , randomize , double-blind , placebo-controlled trial . A total 100 patient , 50 patient per treatment arm , undergo minimally invasive thoracic surgery randomize 1:1 across 2 treatment arm : Ofiramev® ( acetaminophen ) injection 1,000 mg ( 100 mL ) plus patient-controlled analgesia ( PCA ) 100 mL placebo plus PCA . All patient enrol single site.50 patient enrol arm ( placebo/ acetamophin ) . Each subject administer single dose study drug placebo infuse 15-minutes , four time , six hour apart . The duration subject participation ten week . Total duration study expect 52 week . The primary endpoint study amount postoperative narcotic use , patient assessment pain measure validated pain survey , length stay hospital . For postoperative pain assessment , Numeric Rating Scale ( NRS ) use ( NRS : 0-10 ; 0 : pain , 10 : bad pain imaginable ) . Pain evaluate 2-hour interval post-anesthesia care unit follow 4-hour interval patient transfer floor . Nurses blind analgesic method evaluate pain level . Hospital length stay measure date admission date discharge . The study drug , Ofiramev® ( acetaminophen ) injection non-salicylate antipyretic non-opioid analgesic agent . The precise mechanism analgesic antipyretic property acetaminophen establish think primarily involve central action . The study drug clear , colorless formulation acetaminophen intend intravenous infusion package glass vial contain 100 mL 1000 mg acetaminophen ( 10 mg/mL ) . The investigational pharmacy transfer study drug 100 mL bag . The placebo solution consist 100 mL normal saline identical 100 mL bag identical labeling . Prior induction anesthesia subject receive single dose Ofiramev® placebo IV infusion 15 minute . Following first dose , subsequent dose give every 6 hour total 4 dos . Regardless treatment arm , study drug placebo dispense manner . Investigational drug store investigational drug service storeroom and/or pharmacy satellite depend nature drug study . All study drug inventory label IRB identification store separately commercial drug product appropriate security stability condition . OFIRMEV store 20°C 25°C ( 68°F 77°F ) use within 6 hour open . An accurate current accounting dispense return study drug subject maintain ongoing basis member study site staff . The number study drug dispense return subject record Investigational Drug Accountability Record . The study monitor verify document throughout course study . Patients voluntarily withdraw trial reason time . Subjects withdraw study event unplanned conversion open thoracic surgery administration neuraxial opioids . If subject withdrawn treatment due adverse event , subject follow treated Investigator abnormal parameter symptom resolve stabilize .</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Age 1899 year Undergo minimally invasive thoracic surgery UTMB Weight &gt; 50 kg Written inform consent obtain subject Hepatic dysfunction Renal dysfunction Chronic alcohol consumption Acetaminophen sensitivity Opioid tolerance History chronic pain Vulnerable population include pregnant prisoner Extension extrathoracic compartment ( i.e . minimally invasive esophagectomy ) , concomitant chest wall resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>